Revvity, INC 10-Q quarterly reports

Revvity, Inc. announced its second-quarter fiscal year 2026 results, showcasing a 1% revenue increase driven by its Diagnostics segment, while navigating a slight decrease in its Life Sciences segment.

Revvity, Inc. announced its first-quarter fiscal year 2026 financial results, showing a 7% increase in total revenue to $711.1 million, while net income saw a slight decrease compared to the prior year.

Revvity, Inc. reported a 2% increase in Q3 2025 revenue to $698.9 million, though gross and operating margins decreased due to tariffs and unfavorable foreign exchange rates.

Revvity, Inc. reported a 4% increase in Q2 2025 revenue, reaching $720.3 million, driven by growth in both Life Sciences and Diagnostics segments, despite a decline in gross margins.

Revvity, Inc. announces a 2% increase in revenue for Q1 2025, driven by growth in its Diagnostics segment and Software revenue within Life Sciences.

Revvity Inc. saw a modest revenue increase and improved operating margins in the third quarter of 2024, driven by growth in its Diagnostics segment.

Revvity, Inc. experienced a slight revenue decrease in Q2 2024, with a 2% drop compared to the same period last year, alongside a decrease in gross margin, but an increase in operating margin.

Revvity Inc. experienced a 4% decrease in revenue in the first quarter of 2024, primarily due to a decline in its Life Sciences segment, while the Diagnostics segment showed slight growth.